O	0	10	Randomized
O	11	16	phase
O	17	18	3
O	19	27	efficacy
O	28	31	and
O	32	38	safety
O	39	44	trial
O	45	47	of
O	48	56	proposed
B-intervention	57	70	pegfilgrastim
I-intervention	71	81	biosimilar
I-intervention	82	85	MYL
I-intervention	85	86	-
I-intervention	86	91	1401H
O	92	94	in
O	95	98	the
O	99	111	prophylactic
O	112	121	treatment
O	122	124	of
B-condition	125	137	chemotherapy
I-condition	137	138	-
I-condition	138	145	induced
I-condition	146	157	neutropenia
O	157	158	.

O	159	172	Pegfilgrastim
O	173	175	is
O	176	185	indicated
O	186	189	for
O	190	198	reducing
O	199	202	the
O	203	211	duration
O	212	214	of
O	215	226	neutropenia
O	227	230	and
O	231	240	incidence
O	241	243	of
O	244	251	febrile
O	252	263	neutropenia
O	264	266	in
O	267	275	patients
O	276	285	receiving
O	286	295	cytotoxic
O	296	308	chemotherapy
O	308	309	.

O	310	314	Here
O	314	315	,
O	316	322	safety
O	323	326	and
O	327	335	efficacy
O	336	338	of
B-intervention	339	342	MYL
I-intervention	342	343	-
I-intervention	343	348	1401H
O	348	349	,
O	350	351	a
O	352	360	proposed
O	361	374	pegfilgrastim
O	375	385	biosimilar
O	385	386	,
O	387	391	were
O	392	404	investigated
O	405	407	as
O	408	419	prophylaxis
O	420	423	for
O	424	436	chemotherapy
O	436	437	-
O	437	444	induced
O	445	456	neutropenia
O	456	457	.

O	458	462	This
O	463	466	was
O	467	468	a
O	469	474	phase
O	475	476	3
O	476	477	,
O	478	489	multicenter
O	489	490	,
O	491	501	randomized
O	501	502	,
O	503	509	double
O	509	510	-
O	510	515	blind
O	515	516	,
O	517	525	parallel
O	525	526	-
O	526	531	group
O	532	543	equivalence
O	544	549	trial
O	550	552	of
O	553	556	MYL
O	556	557	-
O	557	562	1401H
O	563	565	vs
O	566	574	European
O	575	580	Union
O	580	581	-
O	581	588	sourced
O	589	598	reference
O	599	612	pegfilgrastim
O	612	613	.

B-eligibility	614	622	Patients
I-eligibility	623	627	with
I-eligibility	628	633	newly
I-eligibility	634	643	diagnosed
I-eligibility	644	649	stage
I-eligibility	650	652	II
I-eligibility	652	653	/
I-eligibility	653	656	III
I-eligibility	657	663	breast
I-eligibility	664	670	cancer
I-eligibility	671	679	eligible
I-eligibility	680	682	to
I-eligibility	683	690	receive
I-eligibility	691	692	(
I-eligibility	692	695	neo
I-eligibility	695	696	)
I-eligibility	697	705	adjuvant
I-eligibility	706	718	chemotherapy
I-eligibility	719	723	with
I-eligibility	724	733	docetaxel
I-eligibility	733	734	/
I-eligibility	734	745	doxorubicin
I-eligibility	745	746	/
I-eligibility	746	762	cyclophosphamide
I-eligibility	763	768	every
I-eligibility	769	770	3
I-eligibility	771	776	weeks
I-eligibility	777	780	for
I-eligibility	781	782	6
I-eligibility	783	789	cycles
O	790	794	were
O	795	803	enrolled
O	804	807	and
O	808	818	randomized
O	819	820	2
O	820	821	:
O	821	822	1
O	823	825	to
O	826	827	6
O	828	830	mg
O	831	833	of
O	834	837	MYL
O	837	838	-
O	838	843	1401H
O	844	846	or
B-control	847	856	reference
I-control	857	870	pegfilgrastim
O	871	873	24
O	874	875	h
O	876	877	(
O	877	878	+
O	879	880	2
O	880	881	-
O	881	882	h
O	883	889	window
O	890	895	after
O	896	899	the
O	900	905	first
O	906	908	24
O	909	910	h
O	910	911	)
O	912	917	after
O	918	921	the
O	922	925	end
O	926	928	of
O	929	941	chemotherapy
O	941	942	.

O	943	946	The
O	947	954	primary
O	955	963	efficacy
O	964	972	endpoint
O	973	976	was
O	977	980	the
B-outcome-Measure	981	989	duration
I-outcome-Measure	990	992	of
I-outcome-Measure	993	999	severe
I-outcome-Measure	1000	1011	neutropenia
I-outcome-Measure	1012	1014	in
I-outcome-Measure	1015	1020	cycle
I-outcome-Measure	1021	1022	1
O	1023	1024	(
O	1024	1025	i
O	1025	1026	.
O	1026	1027	e
O	1027	1028	.
O	1028	1029	,
O	1030	1034	days
O	1035	1039	with
O	1040	1048	absolute
O	1049	1059	neutrophil
O	1060	1065	count
O	1066	1067	(
O	1067	1070	ANC
O	1070	1071	)
O	1072	1073	<
O	1074	1075	0
O	1075	1076	.
O	1076	1077	5
O	1078	1079	×
O	1080	1083	109
O	1083	1084	/
O	1084	1085	L
O	1085	1086	)
O	1086	1087	.

O	1088	1092	Mean
O	1093	1094	(
O	1094	1102	standard
O	1103	1112	deviation
O	1113	1114	(
O	1114	1116	SD
O	1116	1117	)
O	1117	1118	)
B-outcome	1119	1127	duration
I-outcome	1128	1130	of
I-outcome	1131	1137	severe
I-outcome	1138	1149	neutropenia
O	1150	1152	in
O	1153	1156	MYL
O	1156	1157	-
O	1157	1162	1401H
O	1163	1166	and
O	1167	1176	reference
O	1177	1190	pegfilgrastim
O	1191	1197	groups
O	1198	1201	was
B-iv-cont-mean	1202	1203	1
I-iv-cont-mean	1203	1204	.
I-iv-cont-mean	1204	1205	2
I-iv-cont-mean	1206	1210	days
O	1211	1212	(
B-iv-cont-sd	1212	1213	0
I-iv-cont-sd	1213	1214	.
I-iv-cont-sd	1214	1216	93
O	1216	1217	)
O	1218	1221	and
B-cv-cont-mean	1222	1223	1
I-cv-cont-mean	1223	1224	.
I-cv-cont-mean	1224	1225	2
I-cv-cont-mean	1226	1230	days
O	1231	1232	(
B-cv-cont-sd	1232	1233	1
I-cv-cont-sd	1233	1234	.
I-cv-cont-sd	1234	1236	10
O	1236	1237	)
O	1237	1238	,
O	1239	1251	respectively
O	1251	1252	.

O	1253	1256	The
O	1257	1259	95
O	1259	1260	%
O	1261	1263	CI
O	1264	1267	for
O	1268	1273	least
O	1274	1281	squares
O	1282	1286	mean
O	1287	1297	difference
O	1298	1299	(
O	1299	1300	-
O	1301	1302	0
O	1302	1303	.
O	1303	1306	285
O	1306	1307	,
O	1308	1309	0
O	1309	1310	.
O	1310	1313	298
O	1313	1314	)
O	1315	1318	was
O	1319	1325	within
O	1326	1329	the
O	1330	1340	predefined
O	1341	1352	equivalence
O	1353	1358	range
O	1359	1361	of
O	1362	1363	±
O	1364	1365	1
O	1366	1369	day
O	1369	1370	.

O	1371	1380	Secondary
O	1381	1390	endpoints
O	1390	1391	,
O	1392	1401	including
B-outcome	1402	1407	grade
I-outcome	1408	1409	≥
I-outcome	1410	1411	3
I-outcome	1412	1423	neutropenia
O	1424	1425	(
O	1425	1434	frequency
O	1434	1435	,
B-iv-bin-percent	1436	1438	91
I-iv-bin-percent	1438	1439	%
O	1440	1443	and
B-cv-bin-percent	1444	1446	82
I-cv-bin-percent	1446	1447	%
O	1448	1451	for
O	1452	1455	MYL
O	1455	1456	-
O	1456	1461	1401H
O	1462	1465	and
O	1466	1475	reference
O	1476	1489	pegfilgrastim
O	1489	1490	,
O	1491	1503	respectively
O	1503	1504	)
O	1504	1505	,
B-outcome	1506	1510	time
I-outcome	1511	1513	to
I-outcome	1514	1517	ANC
I-outcome	1518	1523	nadir
O	1524	1525	(
O	1525	1529	mean
O	1530	1531	(
O	1531	1533	SD
O	1533	1534	)
O	1534	1535	,
B-iv-cont-mean	1536	1537	6
I-iv-cont-mean	1537	1538	.
I-iv-cont-mean	1538	1539	2
O	1540	1541	(
B-iv-cont-sd	1541	1542	0
I-iv-cont-sd	1542	1543	.
I-iv-cont-sd	1543	1545	98
O	1545	1546	)
O	1547	1550	and
B-cv-cont-mean	1551	1552	6
I-cv-cont-mean	1552	1553	.
I-cv-cont-mean	1553	1554	3
O	1555	1556	(
B-cv-cont-sd	1556	1557	1
I-cv-cont-sd	1557	1558	.
I-cv-cont-sd	1558	1560	57
O	1560	1561	)
O	1562	1566	days
O	1566	1567	)
O	1567	1568	,
O	1569	1572	and
B-outcome	1573	1581	duration
I-outcome	1582	1584	of
I-outcome	1585	1589	post
I-outcome	1589	1590	-
I-outcome	1590	1595	nadir
I-outcome	1596	1604	recovery
O	1605	1606	(
O	1606	1610	mean
O	1611	1612	(
O	1612	1614	SD
O	1614	1615	)
O	1615	1616	,
B-iv-cont-mean	1617	1618	1
I-iv-cont-mean	1618	1619	.
I-iv-cont-mean	1619	1620	9
O	1621	1622	(
B-iv-cont-sd	1622	1623	0
I-iv-cont-sd	1623	1624	.
I-iv-cont-sd	1624	1626	85
O	1626	1627	)
O	1628	1631	and
B-cv-cont-mean	1632	1633	1
I-cv-cont-mean	1633	1634	.
I-cv-cont-mean	1634	1635	7
O	1636	1637	(
B-cv-cont-sd	1637	1638	0
I-cv-cont-sd	1638	1639	.
I-cv-cont-sd	1639	1641	91
O	1641	1642	)
O	1643	1647	days
O	1647	1648	)
O	1649	1653	were
O	1654	1664	comparable
O	1664	1665	.

B-outcome	1666	1673	Overall
I-outcome	1674	1680	safety
I-outcome	1681	1689	profiles
O	1690	1692	of
O	1693	1696	the
O	1697	1702	study
O	1703	1708	drugs
O	1709	1713	were
O	1714	1724	comparable
O	1724	1725	.

O	1726	1729	MYL
O	1729	1730	-
O	1730	1735	1401H
O	1736	1748	demonstrated
O	1749	1759	equivalent
O	1760	1768	efficacy
O	1769	1772	and
O	1773	1780	similar
O	1781	1787	safety
O	1788	1790	to
O	1791	1800	reference
O	1801	1814	pegfilgrastim
O	1815	1818	and
O	1819	1822	may
O	1823	1825	be
O	1826	1828	an
O	1829	1839	equivalent
O	1840	1846	option
O	1847	1850	for
O	1851	1859	reducing
O	1860	1869	incidence
O	1870	1872	of
O	1873	1884	neutropenia
O	1884	1885	.

O	1886	1887	(
O	1888	1902	ClinicalTrials
O	1902	1903	.
O	1903	1906	gov
O	1907	1908	,
O	1909	1920	NCT02467868
O	1920	1921	;
O	1922	1929	EudraCT
O	1929	1930	,
O	1931	1935	2014
O	1935	1936	-
O	1936	1942	002324
O	1942	1943	-
O	1943	1945	27
O	1945	1946	)
O	1946	1947	.
